Exciting updates from Richard Francis, CEO of Teva Pharmaceuticals, yesterday at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York City (New York) about the pivotal Phase 3 of Olanzapine LAI powered by Medincell technology: > No PDSS observed after completion of c.c.99% of the targeted injections for submission have been performed as of today > confirmation that the full submission safety results are expected to be available in H2 24. > Replay of the conference available here: https://lnkd.in/dBWQssTM > Press release: https://lnkd.in/dWwvNWD5 Olanzapine LAI is an investigational once-monthly subcutaneous long-acting injection of the atypical antipsychotic Olanzapine. It has the potential to be the first long-acting Olanzapine with a favorable safety profile.
Medincell
Fabrication de produits pharmaceutiques
Jacou, Occitanie 13 983 abonnés
Better Medicine For All
À propos
Better Medicine for All MedinCell is a pharmaceutical company at commercial stage. We develop a portfolio of long-acting injectables in various therapeutic areas. Our proprietary technology BEPO® aims to ensure patient compliance, improve the effectiveness and accessibility of treatments, and reduce their environmental footprint. We collaborate with tier-one pharmaceutical companies and foundations to improve Global Health through new therapeutic options. Our mission is to contribute to the improvement and protection of the health of populations across the world. The fair sharing of the value created with all our employees is the foundation of our business model. The sustainability of MedinCell is an essential condition for achieving our objectives. #BetterMedicineForAll #ImpactHealth #GlobalHealth #ControlledRelease #CreativeThinking #InnovationForward #Science
- Seite web
-
http://www.medincell.com
Lien externe pour Medincell
- Secteur
- Fabrication de produits pharmaceutiques
- Größe des Unternehmens
- 51-200 employés
- Siège social
- Jacou, Occitanie
- Typ
- Société civile/Société commerciale/Autres types de sociétés
- Fondée en
- 2002
- Domains
- pharmaceutical industry, medical devices, drug delivery, API, joint ventures, R&D, global health, Health innovation, pain control, chronic pain, generic, mental health, compliance, patient safety, controlled release, Polymer chemistry, long acting drug et patient care
Lieux
-
Direktorin
3 rue des Frères Lumière
34830 Jacou, Occitanie, FR
Employés chez Medincell
Nouvelles
-
Read our latest press release for a comprehensive update of our product portfolio and R&D pipeline: https://lnkd.in/eCCnkXuP
-
Yesterday Medincell’s partner Teva Pharmaceuticals provided update on pivotal clinical Phase 3 of investigational Olanzapine Long-Acting Injectable (LAI) and UZEDY® commercial progress Read the press release: https://lnkd.in/eiSRJ57u
-
🔬 Our R&D team (represented by Adolfo Lopez Noriega, Charlotte Peloso and Fang Liu) will attend the Controlled Release Society 2024 conference (from July 8 to 12 in Bologna, Italy) to provide an overview of some of our R&D programs related to our cutting-edge Long-Acting Injectable technologies through several presentations and posters, including: - Oncology field: Presentation of in vivo data showing the improved immunomodulatory potential of a tumor-targeting monoclonal antibody in melanoma using BEPO® technology for peritumoral administration. - Introduction to BEPO® STAR: Overview of the novel Medincell’s proprietary Long-Acting Injectable technology designed to enhance controlled delivery across a broader range of drugs and therapeutic areas. - Medincell proprietary in vitro release tool: Presentation of an innovative in vitro lab tool designed to accelerate formulation activities and preclinical candidates selection. #Medincell #CRS2024 #LongActingInjectables #Oncology #Innovation #Pharmaceuticals
-
📻 This morning, Christophe Douat was featured on Radio Classique , interviewed by Charles Bonnaire / François Geffrier on "La France de Demain". It was a great opportunity to highlight the recent successes of Medincell and share what's coming next. 📢 Tune in to listen to the full interview here (in French): https://lnkd.in/e4zDEtUG #Innovation #Succès #Futur #RadioClassique #Interview
-
📈 H.C. Wainwright & Co., LLC, a leader in the U.S. healthcare sector, has initiated coverage of Medincell with a "Buy" rating and a price target of €24, indicating a potential +80% increase! Recent milestones driving this momentum: ✅ FDA approval & successful launch by Teva Pharmaceuticals of UZEDY® for schizophrenia treatment ✅ Positive Phase 3 results for mdc-TJK, a promising new antipsychotic LAI ✅ Collaboration with AbbVie to co-develop and commercialize up to six therapeutic products Read the full PR: https://lnkd.in/eYmUUesj
-
Medincell has joined the prestigious Euronext Tech Leaders index, which features over 110 high-growth tech companies across Europe. This inclusion provides us with access to a specialized ecosystem and international investors, enhancing our growth and innovation journey. This inclusion underscores our sustained growth and leadership in technological innovation. It also enhances Medincell financial strategy by increasing Company visibility to international investors. Full press release: https://lnkd.in/e5Vyk3uV #EuronextTechLeaders
-
"The [Teva Pharmaceuticals] stock surged 13%. The reason: strong results of its once-monthly injectable for schizophrenia." Teva's investigational extended-release olanzapine and the already-approved UZEDY are both powered by MedinCell's Long-Acting Injectable technology. We are proud that our innovative technology is at the core of two major assets in Teva's "Pivot to Growth" strategy. This strong partnership underscores our commitment to advancing healthcare through cutting-edge solutions. Read more in The Wall Street Journal: https://lnkd.in/en8bFgxZ #Pharmaceuticals #Innovation #Healthcare #MedinCell #TevaPharmaceuticals
Israel’s Once-Dominant Drugmaker Is Revived by Innovation
wsj.com
-
To attend the videoconference: https://lnkd.in/gJdj7cxp
-
Exciting News in Schizophrenia Treatment: Teva Pharmaceuticals and Medincell Announce positive efficacy results in SOLARIS Phase 3 Trial We are thrilled to share that our latest Phase 3 trial, SOLARIS, has achieved remarkable success! TEV-749 (olanzapine), a once-monthly subcutaneous long-acting injectable, has met its primary endpoint, showing statistically significant and clinically meaningful reductions in symptom severity as measured by the Positive and Negative Syndrome Scale (PANSS). Key Highlights: Effective Results: All dose groups of TEV-749 demonstrated superior efficacy in reducing schizophrenia symptoms compared to placebo. High Tolerance: TEV-749 was well tolerated, with no cases of post-injection delirium/sedation syndrome (PDSS) observed thus far. Innovative Technology: Leveraging Medincell's proprietary Long-Acting Injectable technology, TEV-749 is designed to provide consistent medication levels with just a once-monthly injection. As our partner continues to gather additional safety data in the ongoing SOLARIS study, it remains committed to advancing this innovative treatment option For more detailed information, click to read the full story: https://lnkd.in/d9YW5Pxj